| abstract |
A process for the preparation of the raf kinase inhibitor sorafenib using a compound of formula (A) wherein R' is selected from -C(O)OA, -C(O)CX3, C(O)NH2, -C(O)-NHON or (a). The process comprises the condensation reaction of the compounds of formula (A) with 4-(4-aminophenoxy)-N-methylpicolinamide, or when R' is (a) the reaction with 4-chloro-N-methyl-2-pyridine in the presence of a base. |